Management of Osteoporosis in Chronic Kidney Disease

1. Yoshimura N, Muraki S, Oka H, et al. Prevalence of knee osteoarthritis, lumbar spondylosis and osteoporosis in Japanese men and women: the research on osteoarthritis/osteoporosis against disability study. J Bone Miner Metab 27: 620-628, 2009.

2. Japanese Society of Nephrology. Evidence-based practice for the treatment of CKD. Clin Exp Nephrol 13: 537-566, 2009.

3. Chen NX, Moe SM. Pathophysiology of vascular calcification. Current Osteoporos Rep 13: 372-380, 2015.

4. Bover J, Urena-Torres P, Lloret MJ, et al. Integral pharmacological management of bone mineral disorders in chronic kidney disease (part II): from treatment of phosphate imbalance to control PTH and prevetion of progression of cardiovascular calcification. Expert Opin Pharmacother 17: 1363-1373, 2016.

5. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA 285: 785-795, 2001.

6. Schipper LG, Fleuren HW, van den, Bergh JP, et al. Treatment of osteoporosis in renal insufficiency. Clin Rheumatol 34: 1341-1345, 2015.

7. Miller PD. Bone disease in CKD: a focus on osteoporosis diagnosis and management. Am J Kidney Dis 64: 290-304, 2014.

8. Orimo H, Hayashi Y, Fukagawa M, et al. Diagnostic criteria for primary osteoporosis: year 2000 revision. J Bone Miner Metab 19: 331-337, 2001.

9. Nickolas TL, McMahon DJ, Shane E. Relationship between moderate to severe kidney disease and hip fracture in the United States. J Am Soc Nephrol 17: 3223-3232, 2006.

10. Alem AM, Sherrard DJ, Gillen DL, et al. Increased risk of hip fracture among patients with end-stage renal disease. Kidney Int 58: 396-399, 2000.

11. Khosla S, Melton J 3rd. Fracture risk in primary hyperparathyroidism. J Bone Miner Res 2 (Suppl): N103-N107, 2002.

12. Fried LF, Briggs MI, Shlipak MG, et al. Association of kidney function with incident hip fracture in older adults. J Am Soc Nephrol 18: 282-286, 2007.

13. Ensrud KE, Lui LY, Taylor BC, et al. Renal function and risk of hip and vertebral fractures in older women. Arch Intern Med 167: 133-139, 2007.

14. Dukas L, Schact E, Stahelin HB. In elderly men and women treated for osteoporosis a low creatinine clearance of <65 ml/min is a risk factor for falls and fractures. Osteoporos Int 16: 1683-1690, 2005.

15. Iimori S, Mori Y, Akita W, et al. Diagnostic usefulness of bone mineral density and biochemical markers of bone turnover in predicting fracture in CKD stage 5D patients-a single-center cohort study. Nephrol Dial Transplant 27: 345-351, 2012.

16. Yenchek RH, Ix JH, Shlipak MG, et al. Bone mineral density and fracture risk in older individuals with CKD. Clin J Am Soc Nephrol 7: 1130-1136, 2012.

17. Naylor KL, Garg AX, Zou G, et al. Comparison of fracture risk prediction among individuals with reduced and normal kidney function. Clin J Am Soc Nephrol 10: 646-653, 2015.

18. West SL, Lok CE, Langsetmo L, et al. Bone mineral density predicts fractures in chronic kidney disease. J Bone Miner Res 30: 913-919, 2015.

19. Jamal SA, Haydenn JA, Beyene J. Low bone mineral density and fractures in long-term hemodialysis patients: a meta-analysis. Am J Kidney Dis 49: 674-681, 2007.

20. Bucur RC, Panjwani DD, Turner L, et al. Low bone mineral density and fractures in stage 3-5 CKD: an updated systematic review and meta-analysis. Osteoporos Int 26: 449-458, 2015.

21. West SJ, Jamal SA. Determination of bone architecture and strength in men and women with stage 5 chronic kidney disease. Semin Dial 25: 397-402, 2012.

22. Salam SN, Eastell R, Khwaja A. Fragility fractures and osteoporosis in CKD: pathophysiology and diagnostic methods. Am J Kidney Dis 63: 1049-1059, 2014.

23. Kuro-O M. A phosphate-centric paradigm for pathophysiology and therapy of chronic kidney disease. Kidney Int 3 (Suppl): 420-426, 2013.

24. Okamoto K, Inaba M, Furumitsu Y, et al. Beneficial effect of risedronate on arterial thickening and stiffening with a reciprocal relationship to its effect on bone mass in female osteoporosis patients: a longitudinal study. Life Sci 87: 686-691, 2010.

25. Kang JH, Keller JJ, Lin HC. Bisphosphonates reduced the risk of acute myocardial infarction: a 5-year follow-up study. Osteoporos Int 24: 271-277, 2013.

26. Maeno Y, Inaba M, Okuno S. Significant association of fracture of the lumbar spine with mortality in female hemodialysis patients: a prospective observational study. Calcif Tissue Int 85: 310-316, 2009.

27. West SL, Patel P, Jamal SA. How to predict and treat increased fracture risk in chronic kidney disease. J Intern Med 278: 19-28, 2015.

28. Miller PD. Bone disease in CKD: a focus on osteoporosis diagnosis and management. Am J Kidney Dis 64: 290-304, 2014.

29. Jamal SA, Bauer DC, Ensrud KE, et at. Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial. J Bone Miner Res 22: 503-508, 2007.

30. Miller PD, Roux C, Boonen S, Barton IP, Dunlap LE, Burgio DE. Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials. J Bone Miner Res 20: 2105-2115, 2005.

31. Miller PD, Raqi-Eis S, Mautalen C, et al. Effects of intravenous ibandronate injection on renal function in women with postmenopausal osteoporosis at high risk for renal disease-the DIVINE study. Bone 49: 1317-1322, 2011.

32. Tanishima S, Morio Y. A review of minodronic acid hydrate for the treatment of osteoporosis. Clin Interv Aging 8: 185-189, 2013.

33. Dhillon S. Zoledronic acid: a review in osteoporosis. Drugs 76: 1683-1697, 2016.

34. Ishani A, Blackwell T, Jamal SA, et al. The effect of raloxifene treatment in postmenopausal women with CKD. J Am Soc Nephrol 19: 1430-1438, 2008.

35. Melamed ML, Blackwell T, Neuqarten J, et al. Raloxifene, a selective estrogen receptor modulator, is renoprotective: a post-hoc analysis. Kidney Int 79: 241-249, 2011.

36. Kondo S, Takano T, Ono Y, Saito H, Matsumoto T. Eldecalcitol reduces osteoporotic fractures by unique mechanisms. J Steroid Biochem Mol Biol 148: 232-238, 2015.

37. Miller PD, Schwartz EN, Chen P, Misurski DA, Krege JH. Teriparatide in postmenopausal women with osteoporosis and mild to moderate renal impairment. Osteoporos Int 18: 59-68, 2007.

38. Jamal SA, Ljunqqren O, Stehman-Breen C, et al. Effects of denosumab on fracture and bone mineral density by level of kidney function. J Bone Miner Res 26: 1829-1835, 2011.

39. Block GA, Bone HG, Fang L, Lee E, Padhi D. A single-dose study of denosumab in patients with various degrees of renal impairment. J Bone Miner Res 27: 1471-1479, 2012.

40. Brown JP, Reid IR, Wagman RB, et al. Effects of up to 5 years of denosumab treatment on bone histology and histomorphology: the FREEDOM study extension. J Bone Miner Res 29: 2051-2056, 2014.